GCM
BIOC

Goldman Capital Management’s Biocept, Inc. BIOC Stock Holding History

Goldman Capital Management’s Portfolio BIOC Stock Details BIOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-11
Closed -$213K – 29
2017
Q1 		$213K Sell
11
-14
-56% -$238K 0.2% 24
2016
Q4 		$176K Buy
+25
New +$209K 0.15% 22

Other funds holding BIOC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $92.2M AUM 19.08% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Capital Management's BIOC Position: Q2 2017 in Review

Goldman Capital Management sold out of Biocept, Inc. (BIOC) in Q2 2017, closing a stake of 11 shares — an estimated $213K sold.

Goldman Capital Management first reported a position in BIOC in Q4 2016 and held it in 2 quarters. The position peaked at $213K in Q1 2017. 15 funds tracked by Wall St. Rank hold BIOC as of Q2 2017.

  • Goldman Capital Management reported no remaining Biocept, Inc. position as of Q2 2017 after selling out during the quarter.
  • Goldman Capital Management sold 11 Biocept, Inc. shares in Q2 2017, an estimated $213K.
  • Goldman Capital Management first reported a position in Biocept, Inc. in Q4 2016 and held it in 2 quarters.
  • Goldman Capital Management's Biocept, Inc. position peaked at $213K in Q1 2017.
  • 15 funds tracked by Wall St. Rank held Biocept, Inc. as of Q2 2017.

Based on Goldman Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.